Metabolic indices in schizophrenia: Association of negative symptoms with higher HDL cholesterol in female patients

References

• Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. 2019. Emerging roles for high-density lipoproteins in neurodegenerative disorders. Biofactors. 45:725–739.
   PubMed Web of Science ®Google Scholar
• Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. 2006. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry. 163:1276–1279.
   PubMed Web of Science ®Google Scholar
• Chen SF, Hu TM, Lan TH, Chiu HJ, Sheen LY, Loh EW. 2014. Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology. Eur Psychiatry. 29:167–171.
   PubMed Web of Science ®Google Scholar
• Fernando P, Sommer IEC, Hasan A. 2020. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia. Curr Opin Psychiatry. 33:192–199.
   PubMed Web of Science ®Google Scholar
• Gjerde BP, Dieset I, Simonsen C, Hoseth EZ, Iversen T, Lagerberg TV, Lyngstad SH, Mørch RH, Skrede S, Andreassen OA, et al. 2018. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. Schizophr Res. 197:253–260.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276.
   PubMed Web of Science ®Google Scholar
• Kim DD, Barr AM, Fredrikson DH, Honer WG, Procyshyn RM. 2019. Association between serum lipids and antipsychotic response in schizophrenia. Curr Neuropharmacol. 17:852–860.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. 2011. The Brief Negative Symptom Scale: psychometric properties. Schizophr Bull. 37:300–305.
   PubMed Web of Science ®Google Scholar
• Koga M, Nakayama K. 2005. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatr Scand. 112:75–77.
   PubMed Web of Science ®Google Scholar
• Li Q, Chen D, Liu T, Walss-Bass C, de Quevedo JL, Soares JC, Zhao J, Zhang XY. 2016. Sex differences in body mass index and obesity in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol. 36:643–648.
   PubMed Web of Science ®Google Scholar
• Lizcano F, Guzman G. 2014. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int. 2014:757461.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Perry E, Jayathilake K. 2003. Clozapine-induced weight gain predicts improvement in psychopathology. Schizoph Res. 59:19–27.
   PubMed Web of Science ®Google Scholar
• Mezquida G, Savulich G, Garcia-Rizo C, Garcia-Portilla MP, Toll A, Garcia-Alvarez L, Bobes J, Mané A, Bernardo M, Fernandez-Egea E. 2018. Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizophr Res. 192:69–74.
   PubMed Web of Science ®Google Scholar
• Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. 2017. Lipid profile disturbances in antipsychotic- naïve patients with first episode non-affective psychosis: a systematic review and metaanalysis. Schizophr Res. 190:18–27.
   PubMed Web of Science ®Google Scholar
• Olszewska K, Rybakowski J. 2009. Clinical improvement and metabolic effects of antipsychotic drugs in schizophrenia. Pharmacother Psychiatry Neurol. 95–100. Polish.
   Google Scholar
• Ono S, Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, et al. 2018. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC Psychiatry. 18:180.
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, et al. 2020. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 7:64–77.
   PubMed Web of Science ®Google Scholar
• Riggs KA, Rohatgi A. 2019. HDL and reverse cholesterol transport biomarkers. Moethodist Debakey Cardiovasc J. 15:39–46.
   PubMedGoogle Scholar
• Samochowiec J, Tyburski E, Misiak B, Editors. 2020. Schizofrenia u mężczyzn (Schizophrenia in males). Warszawa: Medical Education. Polish.
   Google Scholar
• Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. 2015. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat. 11:51–57.
   PubMed Web of Science ®Google Scholar
• Taetzsch A, Roberts SB, Gilhooly CH, Lichtenstein AH, Krauss AJ, Bukhari A, Martin E, Hatch-McChesney A, Das SK. 2020. Food cravings: association with dietary intake and metabolic health. Appetite. 152:104711.
   PubMed Web of Science ®Google Scholar
• Tian Y, Liu D, Wang D, Wang J, Xu H, Dai Q, Andriescue EC, Wu HE, Xiu M, Chen D, et al. 2020. Obesity in Chinese patients witch chronic schizophrenia; prevalence, clinical correlates and relationship with cognitive deficits. Schizophr Res. 215:270–276.
   PubMed Web of Science ®Google Scholar
• Wójciak P, Górna K, Domowicz K, Jaracz K, Gołębiewska K, Michalak M, Rybakowski J. 2019. Polish version of the Brief Negative Symptom Scale (BNSS). Psychiatr Pol. 53:541–549.
   PubMed Web of Science ®Google Scholar
• Wójciak P, Górna K, Domowicz K, Jaracz K, Szpalik R, Michalak M, Różański M, Rybakowski J. 2018. Assessment of negative symptoms in male and female schizophrenia patients using the Polish version of the Brief Negative Syndrome Scale and Self-evaluation of Negative Symptoms. nin. 13:121–127. Polish.
   Google Scholar
• Yang F, Wang K, Du X, Deng H, Wu HE, Yin G, Ning Y, Huang X, Teixeira AL, de Quevedo J, et al. 2019. Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia. Psychopharmacology (Berl). 236:753–762.
   PubMed Web of Science ®Google Scholar
• Ziauddeen H, Alonso-Alonso M, Hill JO, Kelley M, Khan NA. 2015. Obesity and the neurocognitive basis of food reward and the control of intake. Adv Nutr. 6:474–486.
   PubMed Web of Science ®Google Scholar